Novo Nordisk Faces Two Realities: EU Approvals Bolster Pipeline as Canadian Patent Loss and Pricing Pressure Bite
26.05.2026 - 17:41:42 | boerse-global.de
Novo Nordisk is navigating a week of sharp contrasts. The Danish drugmaker secured two key regulatory endorsements in Europe for its obesity drug Wegovy, yet simultaneously had to launch a defensive pricing programme in Canada after losing its Ozempic patent. The mixed signals leave investors weighing near-term headwinds against long-term pipeline promise.
EU green light for oral and high-dose Wegovy
On 22 May, the European Medicines Agency’s CHMP recommended approval for two new Wegovy formulations. The first is a high-dose 7.2 mg once-weekly injection, which delivered an average 20.7% weight loss over 72 weeks in the STEP-UP study — a marked improvement over the standard 2.4 mg dose. The second is a 25 mg oral tablet for adults with obesity, which, if formally approved by the European Commission, would become the first oral GLP-1 treatment for obesity in the EU.
Novo Nordisk expects the 7.2 mg pen to launch in the third quarter of 2026. The oral version is already available in the US and has been gaining steady traction since the start of the year.
Patent slip in Canada triggers price cap
Just days later, on 26 May, Novo Nordisk Canada rolled out an “Extra Savings” programme for Ozempic. The company lost its Canadian patent on the blockbuster diabetes drug due to a filing error, opening the door to cheaper generics. Under the new scheme, patients without insurance will pay no more for the branded product than they would for a generic.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
More than one million Canadians use semaglutide-based medicines. Iain Graham, head of Novo Nordisk Canada, said the programme is designed to let patients stay on the brand they trust. The discount cards are available in pharmacies nationwide — except in Quebec.
POSEIDON study adds scientific depth
Away from the pricing battles, Novo Nordisk presented data from the POSEIDON study at the European Atherosclerosis Congress in Athens. The observational analysis tracked nearly 19,000 patients across 18 countries between 2023 and 2025, making it one of the largest global assessments of cardiovascular inflammation in high-risk populations.
The findings showed that two out of five patients with atherosclerotic cardiovascular disease and chronic kidney disease, and two out of five heart failure patients, had elevated levels of high-sensitivity C-reactive protein (?2 mg/L) — a marker linked to higher risk of heart attack, stroke and cardiovascular death. The company argues that even optimised standard therapy does not eliminate this inflammatory risk, positioning itself as a player across the broader cardiometabolic spectrum.
For investors, the message is less about immediate revenue and more about long-term strategic positioning. Novo Nordisk is trying to establish itself across obesity, diabetes, kidney disease and heart failure, where therapeutic overlap is substantial.
Buyback programme continues
Alongside the clinical and regulatory moves, the company is ploughing ahead with its capital return plan. The DKK 15 billion share buyback programme launched on 4 February runs for twelve months. After completing an initial tranche in early May, a new phase began on 6 May.
By the end of April, Novo Nordisk had repurchased over 13 million B-shares at an average price of around DKK 256.48. The buyback is aimed at reducing capital and serving equity-based compensation plans.
Financial picture remains cautious
The first quarter of 2026 showed a mixed performance. Reported revenues climbed 32% at constant exchange rates, but that figure was heavily flattered by a one-off effect related to the US 340B drug pricing programme. Stripping that out, revenues fell 4%. The obesity segment, on an adjusted basis, grew 22%.
Novo Nordisk at a turning point? This analysis reveals what investors need to know now.
Adjusted operating profit dropped 6% to approximately DKK 32.9 billion in the quarter. For the full year 2026, management expects adjusted revenue and profit growth of between minus 4% and minus 12% at constant exchange rates — a clear signal that pricing pressure and regulatory hurdles are weighing on the outlook.
Market mood subdued
The stock has felt the weight. At the time of the CHMP news, the ADR closed at $44.96, a modest 1.28% gain. Since then, the shares have drifted: the European listing currently trades at €38.70, while the Copenhagen-listed stock sits at around €38.44, down roughly 0.5% on the day. Both are nearly 45% below the 52-week high of €70.13, reflecting the broad correction in pharma stocks.
Analysts remain cautious, noting that the technical uptrend is not yet intact. The high-dose Wegovy launch in the EU during the third quarter could provide a catalyst, but for now, the market is watching whether the company can hold its adjusted full-year guidance while fending off generic competition in Canada and pricing pressure across its GLP-1 franchise.
Ad
Novo Nordisk Stock: New Analysis - 26 May
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
